KHRNF (Khiron Life Sciences) LT-Debt-to-Total-Asset: 0.04 (As of Sep. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Khiron Life Sciences LT-Debt-to-Total-Asset?

Khiron Life Sciences KHRNF -90.00% LT-Debt-to-Total-Asset is 0.04 as of Sep. 2022.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Khiron Life Sciences's long-term debt to total assests ratio for the quarter that ended in Sep. 2022 was 0.04.

Khiron Life Sciences's long-term debt to total assets ratio increased from Sep. 2021 (0.02) to Sep. 2022 (0.04). It may suggest that Khiron Life Sciences is progressively becoming more dependent on debt to grow their business.

Khiron Life Sciences  (OTCPK:KHRNF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Khiron Life Sciences LT-Debt-to-Total-Asset Related Terms

Khiron Life Sciences LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Khiron Life Sciences's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Khiron Life Sciences LT-Debt-to-Total-Asset Chart

Khiron Life Sciences Annual Data
Trend May12 May13 May14 May15 May16 May17 Dec18 Dec19 Dec20 Dec21
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.06 0.03 0.02 0.02

Khiron Life Sciences Quarterly Data
Nov17 Feb18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.02 0.02 0.04 0.04

Khiron Life Sciences LT-Debt-to-Total-Asset Calculation

Khiron Life Sciences's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2021 is calculated as

LT Debt to Total Assets (A: Dec. 2021 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2021 )/Total Assets (A: Dec. 2021 )
=0.551/33.027
=0.02

Khiron Life Sciences's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2022 is calculated as

LT Debt to Total Assets (Q: Sep. 2022 )=Long-Term Debt & Capital Lease Obligation (Q: Sep. 2022 )/Total Assets (Q: Sep. 2022 )
=1.003/28.827
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.04 mean?
Khiron Life Sciences (KHRNF) has a LT-Debt-to-Total-Asset of 0.04 as of Sep. 2022. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Khiron Life Sciences and its competitors.
Is Khiron Life Sciences' LT-Debt-to-Total-Asset too high?
Khiron Life Sciences' current LT-Debt-to-Total-Asset is 0.04.
How does Khiron Life Sciences' LT-Debt-to-Total-Asset compare to ZTS and CTLT?
Khiron Life Sciences' LT-Debt-to-Total-Asset of 0.04 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?
A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Khiron Life Sciences and its competitors. Khiron Life Sciences's current LT-Debt-to-Total-Asset is 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Khiron Life Sciences stock overvalued right now?
Khiron Life Sciences (KHRNF) has a current LT-Debt-to-Total-Asset of 0.04. The current LT-Debt-to-Total-Asset is 0.04. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Khiron Life Sciences (KHRNF), the current LT-Debt-to-Total-Asset is 0.04 as of Sep. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Khiron Life Sciences Business Description

Address 2300 - 500 Burrard Street, Vancouver, BC, CAN, V6C 2B5
Khiron Life Sciences Corp is a vertically integrated medical company with core operations in Latin America and Europe, The company's platform leverages medical health clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific, product innovation, and cannabis operations expertise to drive prescriptions and brand loyalty with patients worldwide. The company has a presence in Mexico, Peru, Germany, the United Kingdom, and Brazil.